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Abstract
Background
The fixed dose combination of artemether-lumefantrine (AL) is the most widely used treat-
ment for uncomplicated Plasmodium falciparum malaria. Relatively lower cure rates and
lumefantrine levels have been reported in young children and in pregnant women during
their second and third trimester. The aim of this study was to investigate the pharmacoki-
netic and pharmacodynamic properties of lumefantrine and the pharmacokinetic properties
of its metabolite, desbutyl-lumefantrine, in order to inform optimal dosing regimens in all
patient populations.
Methods and findings
A search in PubMed, Embase, ClinicalTrials.gov, Google Scholar, conference proceedings,
and the WorldWide Antimalarial Resistance Network (WWARN) pharmacology database
identified 31 relevant clinical studies published between 1 January 1990 and 31 December
2012, with 4,546 patients in whom lumefantrine concentrations were measured. Under the
auspices of WWARN, relevant individual concentration-time data, clinical covariates, and
outcome data from 4,122 patients were made available and pooled for the meta-analysis.
The developed lumefantrine population pharmacokinetic model was used for dose optimisa-
tion through in silico simulations. Venous plasma lumefantrine concentrations 7 days after
starting standard AL treatment were 24.2% and 13.4% lower in children weighing <15 kg
and 15–25 kg, respectively, and 20.2% lower in pregnant women compared with non-preg-
nant adults. Lumefantrine exposure decreased with increasing pre-treatment parasitaemia,
and the dose limitation on absorption of lumefantrine was substantial. Simulations using the
lumefantrine pharmacokinetic model suggest that, in young children and pregnant women
beyond the first trimester, lengthening the dose regimen (twice daily for 5 days) and, to a
lesser extent, intensifying the frequency of dosing (3 times daily for 3 days) would be more
efficacious than using higher individual doses in the current standard treatment regimen
(twice daily for 3 days). The model was developed using venous plasma data from patients
receiving intact tablets with fat, and evaluations of alternative dosing regimens were conse-
quently only representative for venous plasma after administration of intact tablets with fat.
The absence of artemether-dihydroartemisinin data limited the prediction of parasite killing
rates and recrudescent infections. Thus, the suggested optimised dosing schedule was
based on the pharmacokinetic endpoint of lumefantrine plasma exposure at day 7.
Conclusions
Our findings suggest that revised AL dosing regimens for young children and pregnant
women would improve drug exposure but would require longer or more complex schedules.
These dosing regimens should be evaluated in prospective clinical studies to determine
whether they would improve cure rates, demonstrate adequate safety, and thereby prolong
the useful therapeutic life of this valuable antimalarial treatment.
WWARN pooled lumefantrine PK analysis
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Author summary
Why was this study done?
• Artemether-lumefantrine (AL) is the most widely used treatment for uncomplicated
Plasmodium falciparum malaria, and lower cure rates and lumefantrine exposures have
been reported in children below 5 years of age and pregnant women.
• Pharmacokinetic-pharmacodynamic trials are generally small, and differences in study
designs limit the generalisability of the findings.
• It is crucial to develop an optimised dose regimen that achieves equivalent drug expo-
sure in all patient groups.
What did the researchers do and find?
• Lumefantrine concentration-time data from 4,122 patients from 26 studies were collated
and pooled for an individual participant data meta-analysis.
• A population pharmacokinetic-pharmacodynamic model was developed for lumefan-
trine to understand how body weight, pregnancy, and baseline parasite density influence
drug levels.
• Small children and women during their second and third pregnancy trimester displayed
lower lumefantrine exposures than non-pregnant adults when receiving the recom-
mended 3-day dosing regimen.
• The developed lumefantrine population pharmacokinetic model was used to evaluate 3
alternative dosing regimens.
• A 5-day regimen of current weight-based standard twice-daily doses for small children
and pregnant women beyond their first trimester is most favourable from a pharmaco-
logical perspective.
What do these findings mean?
• The proposed AL dosing regimen is expected to provide equivalent lumefantrine expo-
sures safely in all patients as well as to expose one additional asexual life cycle to arte-
mether-dihydroartemisinin.
• The proposed dosing regimen should not only increase cure rates and slow resistance
development but also prolong the useful therapeutic life of AL.
Introduction
Malaria is a major infectious disease in tropical countries, with an estimated 212 (range 148–
304) million infections and 429,000 (range 235,000–639,000) deaths in 2015 [1]. Over 90% of
the global malaria mortality is reported in sub-Saharan Africa. Children under 5 years of age
WWARN pooled lumefantrine PK analysis
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are the most vulnerable, accounting for 70% of all malaria-related deaths [1]. The World
Health Organization recommends that uncomplicated Plasmodium falciparum malaria should
be treated with an artemisinin-based combination therapy (ACT) [2]. Artemether-lumefan-
trine (AL) is the most widely used ACT, accounting for 73% of global ACT procurement in
2013 [3], which makes it one of the most widely used anti-infective agents in the world today.
Furthermore, AL is well tolerated and safe for the treatment of uncomplicated P. falciparum
(and other malaria species) infections in all age groups. This includes young children and preg-
nant women in their second and third trimesters, groups with increased morbidity and mor-
tality from falciparum malaria [2]. Sub-optimal drug exposures have been reported following
currently recommended doses of AL both in young children and pregnant women in their
second and third trimesters [4–12]. On the other hand, similar exposure in pregnant women
during their second and third trimester compared to non-pregnant women has also been
observed, although the non-pregnant women in this study might not have been as symptom-
atic as the pregnant women [13]. Moreover, the numbers of patients recruited to these clinical
trials were generally small, and differences in study design including selection of comparator
therapies and dose regimens and co-administration with fat [14,15] all limit the generalisability
of the findings. A meta-analysis could potentially overcome this by pooling individual patient
level data from several different studies and characterising both pharmacological properties
and the influence of differences in study design, study size, comparator therapies, dose regi-
mens, and inconsistent co-administration with fat. Lumefantrine exposure at day 7 has been
evaluated in a meta-analysis previously, but not using a dynamic modelling approach to char-
acterise and quantify pharmacological properties, the influence of covariates, and the relation-
ship between drug concentrations and study outcome [16].
The aim of this study was to assemble a large and therefore sufficiently powered pooled
dataset of patients to examine the pharmacokinetic properties of lumefantrine. This approach
enabled critical re-evaluation of the current twice-daily 3-day dosing regimen of AL, particu-
larly in children and in pregnant women in their second and third trimesters. As both lume-
fantrine and its principal metabolite, desbutyl-lumefantrine, have antimalarial activity, we also
designed a pharmacokinetic analysis incorporating both compounds.
Methods
Model building
Pharmacokinetic data, clinical covariates, and efficacy data from patients treated with AL were
used for this individual patient data meta-analysis. A search was conducted in PubMed,
Embase, ClinicalTrials.gov, Google Scholar, conference proceedings, and the WorldWide
Antimalarial Resistance Network (WWARN) pharmacology publication database to identify
relevant antimalarial clinical studies published between 1 January 1990 and 31 December 2012
[16] in which pharmacokinetic parameters as well as clinical covariates in patients treated with
AL were recorded. The search strategy used key terms “lumefantrine pharmacokinetics” or
“lumefantrine concentration” and “clinical study”.
Under the auspices of WWARN, investigators were invited to participate in this individual
patient data meta-analysis. Individual study protocols were available for all trials included,
either from the publication or as a metafile submitted with the raw data. Individual patient
data from eligible studies were shared, standardised, and collated using a methodology
described in the WWARN clinical and pharmacology data management and statistical analysis
plans [17,18] and previously published research [16].
Concentration-time data and clinical covariates from patients contributing 2 or more
venous plasma samples were used to build the pharmacokinetic models. Patients contributing
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only 1 pharmacokinetic sample could not be used for model development as between-patient
variability could not be dissected from residual variability. Lumefantrine concentration data in
different sampling matrices (i.e., venous blood and capillary plasma and blood) and lumefan-
trine concentration data after administration of different formulations (i.e., crushed tablets
and dispersible tablets) were not used for the formal pharmacokinetic model development due
to the sparse sampling schedules (i.e., <2 samples per patient for crushed tablets, dispersible
tablets, venous blood, and capillary blood) and to avoid introducing additional sources of vari-
ability (i.e., capillary plasma samples). Consequently, lumefantrine concentration-time data in
venous blood, capillary blood, and capillary plasma as well as lumefantrine concentration-time
data from dispersible tablets and crushed tablets were evaluated using a post hoc correction
factor at residual variability level with all other pharmacokinetic parameters fixed. Patients
contributing <2 venous plasma samples were used for external validation of the developed
population pharmacokinetic models.
Both a lumefantrine population pharmacokinetic model and a separate lumefantrine/des-
butyl-lumefantrine population pharmacokinetic drug-metabolite model were developed. The
natural logarithms of the concentration data were modelled in NONMEM v.7.3 (ICON Devel-
opment Solutions, Ellicott City, MD) on a Windows XP operating system (Microsoft, Seattle,
WA) with a G95 Fortran compiler (Free Software Foundation, Boston, MA).
The developed lumefantrine population pharmacokinetic model was used to generate indi-
vidual post hoc pharmacokinetic parameter estimates. The resulting lumefantrine concentra-
tion-time profiles were subsequently used to link lumefantrine plasma concentrations and
clinical study outcome (i.e., cure defined as absence of PCR-corrected recrudescent infection
during follow-up) using a time-to-event approach (pharmacokinetic-pharmacodynamic time-
to-event model). All outcome data later than day 42 were censored at day 42, and novel infec-
tions were censored. The lumefantrine/desbutyl-lumefantrine drug-metabolite model was not
combined with the time-to-event approach due to the small sample size relative to the lume-
fantrine population pharmacokinetic model.
More technical information regarding the pharmacokinetic model building process and the
pharmacokinetic-pharmacodynamic time-to-event model building process can be found in
S1 Text.
Dose optimisation simulations
The developed lumefantrine pharmacokinetic model was subsequently used for in silico
evaluation and comparison of 3 alternative dosing regimens, with plasma lumefantrine con-
centration on day 7 selected as the pharmacokinetic endpoint [19,20]. This pharmacokinetic
endpoint has been used as a target for AL treatment as it correlates with cure rate. The day 7
concentration reflects lumefantrine exposure over the previous 3 asexual cycles (i.e., 6 days for
P. falciparum) [19,20]. Plasma or whole blood [21] lumefantrine concentration on day 7 there-
fore constitutes a clinically relevant and practical surrogate of overall drug exposure, with sug-
gested target day 7 lumefantrine concentrations of 175 ng/ml, 200 ng/ml, and 280 ng/ml in
different studies [12,16,22,23].
A variety of alternative dosing regimens for young children and pregnant women were sim-
ulated, and lumefantrine pharmacokinetic parameters were compared to those following
administration of the standard dose regimen in non-pregnant adults. Alternative dosing regi-
mens included an increased dosage (1 extra tablet containing 20 mg artemether and 120 mg
lumefantrine added to current weight-based standard dose at each twice-daily dose for 3 days),
an extended treatment (5-day regimen of current weight-based standard twice-daily doses),
and an intensified treatment (current weight-based standard dosage administered 3 times
WWARN pooled lumefantrine PK analysis
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daily for 3 days). More technical information regarding the in silico dose optimisation simula-
tions can be found in S1 Text.
Ethical approval
All data included in this analysis were obtained in accordance with the laws and ethical
approvals applicable in the countries in which the studies were conducted, and were from clin-
ical studies in which blood samples were obtained with the knowledge and consent of the indi-
viduals to which they relate. Data were fully anonymised either before or during the process of
uploading to the WWARN pharmacology database. Ethical approval to conduct individual
participant data pooled analyses was granted to WWARN by the Oxford Tropical Research
Ethics Committee (OxTREC).
Results
Lumefantrine concentration-time data from 4,122 patients from 26 studies were uploaded to
the WWARN pharmacology database (Fig 1; S1 Table). These data were categorised into 3 dif-
ferent geographic areas (Africa, Oceania, and Southeast Asia) comprising 12 countries (Benin,
Guinea-Bissau, Tanzania, Uganda, Kenya, Mali, Mozambique, Liberia, Papua New Guinea,
Lao People’s Democratic Republic [Laos], Thailand, and Cambodia). Lumefantrine concentra-
tions were available for analysis in 4 different matrices: 2,312 patients contributed venous
plasma samples, 595 patients contributed venous whole blood samples, 191 patients contrib-
uted capillary plasma samples, and 840 patients contributed capillary whole blood samples. In
total, 154 patients were excluded from the analysis, 71 because of missing dosing information
and 83 who took repeated dosing (i.e., retreatment). A further 30 patients were excluded from
the evaluation of pre-treatment parasitaemia as a covariate because relevant parasitological
data were missing. Venous plasma data from 1,347 out of 2,312 patients who contributed at
least 2 samples was used for the development of the lumefantrine population pharmacokinetic
model. The remaining 400, 278, and 287 patients contributed only 1 venous plasma sample
per patient after treatment with intact, crushed, and dispersible tables, respectively, and were
therefore only used for external validation and evaluation of formulation effects in a separate
analysis (Table 1). Approximately 37% of the patients were children below 10 years of age and
3.12% were pregnant women (median [range: interquartile range] 23.0 [13.1–38.0: 19.1–30.0]
weeks gestational age). Data from 3,486 patients were available for the development of the
pharmacokinetic-pharmacodynamic time-to-event model. Approximately 59% of the patients
were below 10 years of age and 4.7% were pregnant women (median [range: interquartile
range] 22.0 [13.1–39.0: 18.5–28.0] weeks gestational age). Venous plasma data from 159
patients were used for the development of the simultaneous lumefantrine/desbutyl-lumefan-
trine population pharmacokinetic model. Approximately 57% of the patients were below 10
years of age and 8.81% were pregnant women (median [range: interquartile range] 23.4 [16.2–
38.0: 20.8–30.4] weeks gestational age).
The following covariates were selected prospectively and their influence evaluated using a
population modelling approach: body weight, pregnancy, estimated gestational age, baseline
parasitaemia, dosage (mg/kg), dose per occasion (mg), total daily dose (mg), total dose (mg),
and age-for-weight z-score. Some clinically relevant covariates were not available for all
patients; these included haemoglobin (available for 2,901 patients; either directly measured or
calculated from measured haematocrit [44]) and baseline body temperature (axillary available
for 3,029 patients, tympanic available for 427 patients, and oral available for 100 patients).
Pooling of temperature data (i.e., axillary, oral, and tympanic) was considered unreliable due
to potential discrepancies between study-site procedures and was therefore not performed. A
WWARN pooled lumefantrine PK analysis
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002579 June 12, 2018 6 / 27
Relevant clinical studies in paents idenﬁed
31 studies and
6,994 clinical paents
including 4,546 PK paents and
9,709 concentraons
Contributed to WWARN repository
26 clinical studies and
6,229 paents including
4,122 PK paents and
9,258 concentraons
26 studies in paents available for 
the meta-analysis
(N = 3,938)
Five clinical studies in paents were not 
contributed
including 424 paents and
458 concentraons
Not willing to share or data lost
Nine clinical studies in healthy volunteers 
were not contributed
including 205 healthy volunteers and 
4,670 concentraons
Not compable study design
71 paents and
71 lumefantrine concentraons
Excluded: no matching dose records
83 paents and
98 lumefantrine concentraons
Excluded: repeated dosing given
30 paents and
122 lumefantrine concentraons
Excluded: no parasite biomass (removed 
from ﬁnal covariate model)
Fig 1. Patient data disposition. PK, pharmacokinetic; WWARN, WorldWide antimalarial resistance Network.
https://doi.org/10.1371/journal.pmed.1002579.g001
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separated covariate analysis was performed on a subset of data in order to evaluate baseline
body temperature and haemoglobin as covariates.
Lumefantrine pharmacokinetic model
Structural model. The lumefantrine pharmacokinetic model was developed based on
data from 1,347 patients. This subset contained relatively densely sampled venous plasma data
(i.e., 2 or more samples per patient) and covered a wide range of covariates (Table 1). Disposi-
tion pharmacokinetics was best described using a 2-compartment model, as this model was
superior to a 1-compartment model (p< 0.001; Δ−2LL = −2,361; ΔAIC = −2,357). The addi-
tion of a third compartment did not result in further significant improvement (p> 0.01; Δ
−2LL = −6.97, ΔAIC = −2.97). A first-order absorption model described the lumefantrine
absorption characteristics adequately, and residual variability was described using an additive
error model on logarithmic data (Fig 2).
Disease- and dosage-related covariate model. Day 7 lumefantrine concentrations
decreased with increasing pre-treatment parasitaemias described using a power relationship
between bioavailability and pre-treatment parasite count (F ¼ yðnÞ  eyparasitaemia  ðparasitaemia  4:2Þ;
coefficient −0.643; p< 0.001; Δ−2LL = −49.4; ΔAIC = −47.4; Table 2). Moreover, lumefantrine
displayed dose-limited absorption, which was parameterised in the model using a maturation
effect (50% saturation of the absorption [dose50] at 3.42 mg/kg; dose90 at approximately 36
mg/kg) on relative bioavailability (p< 0.001; Δ−2LL = −64.6; ΔAIC = −62.6; Table 2).
Children. The currently recommended 6-dose regimen in children weighing <15 kg and
15–24 kg resulted in 24.2% and 13.4% lower predicted median venous lumefantrine concen-
trations at day 7, respectively, when compared to adult patients (Fig 3). This resulted from
body weight, implemented as a covariate on clearance (CL and Q ¼ y nð Þ  WT
42
3
4) and volume
(V ¼ y nð Þ  WT
42
) parameters (p< 0.001; Δ−2LL = −271; ΔAIC = −271; Table 2).
Furthermore, weight-for-age z-scores [45] were calculated and tested as a linear covariate
for children below 5 years of age (n = 281) or below 3 years of age (n = 139). Weight-for-age z-
scores did not correlate with pharmacokinetic parameters in any of the tested age ranges, and
age as a proxy for hepatic enzyme maturation did not significantly improve the model fit when
included as a covariate on elimination clearance.
Pregnant women. Lumefantrine distribution kinetics was substantially affected in preg-
nant women during their second and third trimester when compared to non-pregnant adults
(p< 0.001; Δ−2LL = −21.8; ΔAIC = −19.8; Table 2), resulting in 20.2% lower day 7 venous
lumefantrine concentrations (ka = θ(n) × (1 + θpregnancy)).
Baseline body temperature and haemoglobin
Haemoglobin and admission body temperature were not formally evaluated using a stepwise
modelling approach in the population pharmacokinetic model as these covariates were miss-
ing for more than 20% of the patients. However, the covariates were evaluated in a separate
sub-group covariate analysis, and baseline body temperature did not correlate with any lume-
fantrine pharmacokinetic parameter in the current population pharmacokinetic model. Mea-
sured or haematocrit-derived haemoglobin concentration was available for 74% of the patients
and correlated significantly with lumefantrine inter-compartmental clearance (p< 0.001; Δ
−2LL = −19.3; ΔAIC = −17.3; exponential relationship with an exponent of 0.0629) and appar-
ent peripheral distribution volume (p< 0.001; Δ−2LL = −11.5; ΔAIC = −9.5; power relation-
ship with a power of 1.44). This correlation resulted in increasing day 7 venous plasma
lumefantrine concentrations with higher haemoglobin levels.
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Model validation. The final model showed accurate and precise predictive power without
indications of model misspecification, using internal data as well as external validation data
from 401 patients with sparse venous plasma sampling (Table 1; Figs 2, S1 and S2). The boot-
strap diagnostics (n = 1,000) confirmed robust parameter estimates with reasonable relative
standard errors (Table 2). Eta-shrinkage on apparent volume of distribution of the central
compartment and relative bioavailability was 47.5% and 15.2%, respectively.
More technical information regarding the lumefantrine pharmacokinetic model can be
found in S2 Text.
Fig 2. Prediction-corrected visual predictive checks. (A) Prediction-corrected visual predictive check of the
lumefantrine population pharmacokinetic model, with the insert representing the first 15 hours after dose. (B and C)
Prediction-corrected visual predictive check of the lumefantrine/desbutyl-lumefantrine drug-metabolite model
stratified for lumefantrine (B) and desbutyl-lumefantrine (C). The inserts in (B) and (C) show the predictive
performance during the first 110 hours after dose. Open circles represent observed plasma concentration data. The
solid lines represent the 5th, 50th, and 95th percentiles of the observed data. The grey shaded areas represent the 95%
confidence intervals of the simulated (n = 2,000) percentiles.
https://doi.org/10.1371/journal.pmed.1002579.g002
Table 2. Population parameter estimates from the final lumefantrine pharmacokinetic model.
Parameter Fixed effects Random effects
Population estimate
(BS estimate)
%RSE (95% CI) %CV for IIV
(BS estimate)
%RSE (95% CI)
F 1 (fixed) — 70.3 (70.2) 5.95 (65.3–75.3)
Box–Cox shape parameter on F −0.343 (−0.342) 19.5 (−0.469 to 0.215) — —
ka (h−1) 0.0386 (0.0388) 2.72 (0.0368 to 0.0410) — —
CL/F (l/h) 1.35 (1.36) 29.7 (0.538 to 2.19) — —
VC/F (l) 11.2 (11.6) 30.3 (4.65 to 18.8) 144 (141) 10.8 (115–165)
Q/F (l/h) 0.344 (0.350) 29.8 (0.137 to 0.566) — —
VP/F (l) 59.0 (59.5) 29.7 (23.6 to 96.4) — —
Dose50 (mg/kg) on F 3.86 (4.07) 41.5 (1.25 to 8.04) — —
Pregnancy on ka 0.352 (0.355) 21.2 (0.212 to 0.510) — —
Parasitaemia on F −0.643 (−0.635) 13.0 (−0.793 to 0.473) — —
σ 0.323 (0.323) 4.88 (0.293 to 0.357) — —
Coefficient of variation (%CV) for inter-individual variability (IIV) was calculated as 100
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
eestimate   1
p
. The relative
standard error (%RSE) was calculated as 100 Standard deviationAverage parameter estimate from 1,000 iterations of a non-parametric bootstrap
(BS) procedure. The 95% confidence interval (95% CI) is displayed as the 2.5th to 97.5th percentile of the BS
estimate, and the BS estimate as the average value.
F: relative bioavailability; Box–Cox shape parameter: shape parameter on Box–Cox transformation; ka: absorption
rate constant; CL/F: elimination clearance; VC/F: apparent central volume of distribution; Q/F: inter-compartmental
clearance; VP/F: apparent peripheral volume of distribution; dose50: dose (mg/kg) needed for half of maximum dose-
dependent saturation of F; pregnancy: categorical covariate effect of pregnancy on ka; parasitaemia: continuous
covariate effect of enrolment parasite density on F; and σ: additive residual error on log scale. All parameters were
centred on a non-pregnant patient weighing 42 kg with an admission parasitaemia of 15,800 parasites/μl.
Clearance and volume parameters were centred on the median body weight (WT) and scaled allometrically
(CL and Q ¼ y nð Þ  WT
42
3
4; V ¼ y nð Þ  WT
42
); dose-dependent absorption was implemented as a saturation model
(F ¼ y nð Þ  1   Dosage
yDosage50þDosage
 
); baseline parasitaemia was implemented as an exponential relationship centred on
the median natural logarithm transformed value (F ¼ yðnÞ  ðeyparasitaemia  ðparasitaemia  4:2ÞÞ), and the categorical pregnancy
effect was implemented as a proportional effect (ka = θ(n) × (1 + θpregnancy)).
https://doi.org/10.1371/journal.pmed.1002579.t002
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Matrix and formulation effects. Prediction-corrected visual predictive checks for matrix-
and formulation-related subsets of the data were generated from the lumefantrine model on
venous plasma data using proportional adjustment and showed adequate predictive perfor-
mance except for capillary plasma (S2 Fig). Only venous blood data displayed a minor over-
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Fig 3. Body weight, pregnancy status, admission parasitaemia, and dosage effects on predicted day 7 venous plasma lumefantrine concentrations (n = 2,000).
Body weight (top left); pregnancy status (top right); admission parasitaemia (bottom left); dosage (bottom right). Boxes and whiskers represent 25%–75% and 2.5%–
97.5% of the data, respectively. The grey solid, dashed, and dotted lines represent 596 ng/ml (median lumefantrine concentration at day 7 in non-pregnant adult patients
after a standard treatment), 200 ng/ml [16], and 175 ng/ml [23], respectively. The dotted black line in the parasitaemia panel represents the mean of the simulated data
(open grey circles).
https://doi.org/10.1371/journal.pmed.1002579.g003
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prediction of the 5th and 95th percentiles (S2 Fig), although mean trends could still be pre-
dicted accurately, and estimated proportional differences in lumefantrine exposures would
therefore be unbiased. Lumefantrine concentrations were on average 11.3%, 18.3%, and 23.8%
lower in studies measuring venous blood (n = 595), capillary plasma (n = 191), and capillary
blood (n = 840), respectively, when compared to the studies measuring lumefantrine in venous
plasma after intact tablets (Table 1; S2 Fig). Venous plasma lumefantrine concentrations in
studies where patients received dispersible (n = 287) and crushed (n = 278) tablets were on
average 6.31% and 26.0% higher, respectively, when compared to studies measuring lumefan-
trine in venous plasma after intact tablets (Table 1; S2 Fig).
Pharmacokinetic-pharmacodynamic time-to-event model
For the pharmacokinetic-pharmacodynamic time-to-event model, individual pharmacokinetic
parameter estimates from 3,486 patients were fixed and evaluated with the treatment outcome
at day 42 (Table 3). Overall, 93 out of 3,486 patients (2.67%) had recrudescent infections. A
Gompertz hazard model with a sigmoidal EMAX lumefantrine drug effect model provided
accurate predictive power in the visual predictive check (Fig 4), but parameter estimates lacked
precision and accuracy (Table 3). No statistically significant covariates were found for the
pharmacodynamic parameters in the full dataset, which could be a consequence of biased dis-
tribution of covariates over the geographical regions and the small number of recrudescent
infections.
To avoid these potential biases, 3 separate pharmacokinetic-pharmacodynamic time-to-
event models were used to evaluate 1,210 African children weighing <15 kg (n = 36; 2.98%
recrudescence), 638 African children weighing 15–25 kg (n = 7; 1.10% recrudescence), and
113 Southeast Asian pregnant women (n = 11; 9.73% recrudescence) (Fig 4; Table 3). Data
from Southeast Asian pregnant women and African children were best described using a con-
stant baseline hazard model with an EMAX lumefantrine drug effect. All pharmacokinetic-
Table 3. Parameter estimates from the pharmacokinetic-pharmacodynamic time-to-event model.
Parameter Day 42 study outcome
All data African children <15 kg African children 15–25
kg
Southeast Asian
pregnant women
Population
estimate
(BS
estimate)
%RSE
(95% CI)
Population
estimate
(BS
estimate)
%RSE
(95% CI)
Population
estimate
(BS
estimate)
%RSE
(95% CI)
Population
estimate
(BS
estimate)
%RSE
(95% CI)
Baseline
hazard
(day−1)
0.00600
(0.0103)
110
(0.00231–
0.0406)
0.00120
0.00120
23.4
(0.000775–
0.00199)
0.00168
0.00264
158
(0.000370–
0.00893)
0.00324
0.00329
30.8
(0.00149–
0.00535)
Hazard
half-life
(day)
12.8
(14.3)
67.4
(6.92–
31.8)
— — —
IC50 (ng/
ml)
92.6
(94.7)
56.0
(10.3–
202)
194
(465)
457
(35.2–
2,410)
9.79
(18.5)
162
(0.703–
87.1)
1,580
(863)
38.4
(307–
1,600)
Slope 1.87
(2.98)
181
(0.979–
9.46)
— — —
The relative standard error (%RSE) was calculated as 100 Standard deviationAverage parameter estimate from 1,000 iterations of a non-
parametric bootstrap (BS) procedure.
IC50, half maximal inhibitory concentration.
https://doi.org/10.1371/journal.pmed.1002579.t003
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pharmacodynamic time-to-event models in these particular populations displayed accurate
predictive power (Fig 4) in the visual predictive check, although parameter estimates lacked
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Fig 4. Visual predictive check of the pharmacokinetic-pharmacodynamic time-to-event model. The grey shaded area represents the 95% confidence interval of the
simulated (n = 2,000) data. Solid and dashed black lines represent the Kaplan–Meier estimator and corresponding standard errors. Panels show all data (top left),
African children<15 kg (top right), African children15 kg and<25 kg (bottom left), and pregnant women from Southeast Asia (bottom right).
https://doi.org/10.1371/journal.pmed.1002579.g004
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precision and accuracy (Table 3). Moreover, pregnancy was not a statistically significant covar-
iate when data from pregnant and (matched) non-pregnant women in Southeast Asia only
were analysed. Furthermore, no statistically significant covariates were found in the pharma-
cokinetic-pharmacodynamic time-to-event model in African children.
In silico dose optimization
As lumefantrine exposures were lower in young children and pregnant women, 3 alternative
dosing regimens were evaluated and compared. A dose increase for pregnant women in their
second and third trimester (100 mg artemether and 600 mg lumefantrine twice daily for 3
days, i.e., 1 extra tablet per dose) and for children weighing between 5 kg and 25 kg (lumefan-
trine doses: 120 mg for children 5–6 kg, 180 mg for children 7–8 kg, 240 mg for children 9–13
kg, and 360 mg for children 14–23 kg, twice daily for 3 days) did not result in equivalent lume-
fantrine concentrations at day 7 compared to a non-pregnant adult population receiving the
standard dose (S3 Fig). However, the intensified dosing regimen (standard dose at 0, 8, 16, 24,
32, 40, 48, 56, and 64 hours) resulted in similar lumefantrine concentrations at day 7 compared
to a non-pregnant adult population receiving the standard treatment (Fig 5). An extended dos-
ing regimen (standard dose twice daily for a total 5 days) displayed the highest probability of
target attainment, with>75% of the simulated lumefantrine concentrations at day 7 above the
mean lumefantrine concentration at day 7 in a non-pregnant adult population receiving
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Fig 5. In silico dose optimisations using Monte Carlo simulations (n = 2,000) with the final lumefantrine pharmacokinetic model for the different populations
consisting of children weighing<15 kg, 15–24 kg, and 25–34 kg; non-pregnant adults35 kg; and pregnant women. The left, middle, and right column represent
the results after a standard, intensified, and extended dosing regimen, respectively. The boxes and whiskers represent 25%–75% and 2.5%–97.5% of the data,
respectively. The horizontal dashed-dotted grey line in the upper panels represents the median lumefantrine concentration at day 7 after standard treatment in non-
pregnant adult patients (801 ng/ml). The dashed and dotted grey horizontal lines in the upper panels represent previously defined lumefantrine day 7 target
concentrations of 175 and 200 ng/ml [16,23]. The horizontal grey dashed lines in the middle and lower panels represent the median lumefantrine area under the curve
(AUC) (647,025 h × ng/ml) and maximum concentration (CMAX) (6,731 ng/ml) after standard treatment in a non-pregnant adult patient population.
https://doi.org/10.1371/journal.pmed.1002579.g005
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standard treatment (Fig 5). Total exposure and maximum lumefantrine concentrations were
similar after intensified (thrice daily) and extended (5 day) dosing regimens and were substan-
tially higher than those with an increased dosing regimen (Figs 5 and S3).
Lumefantrine/desbutyl-lumefantrine pharmacokinetic model
The lumefantrine/desbutyl-lumefantrine pharmacokinetic model was developed based on data
from 159 patients contributing 2 or more venous plasma samples per patient with a wide
range of covariates (Table 1). A 2-compartment distribution model provided a substantial
improvement of the model fit (p< 0.001; Δ−2LL = −281; ΔAIC = −277) compared to a 1-com-
partment distribution model, but the addition of a third disposition compartment did not
improve the model further (p> 0.01; Δ−2LL = −8.68; ΔAIC = −4.68) (Table 4). Apart from the
effect of body weight on clearance and volume parameters, no further covariates were included
in the model. Unfortunately, a robust evaluation of pregnancy was not possible due to the
small sample size (Table 1). The basic goodness-of-fit plots and parameter estimates showed a
robust model without indications of model misspecification (S4 Fig). The predictive power
was accurate considering the sampling design and sample size (Figs 2 and S5).
More technical information regarding the lumefantrine/desbutyl-lumefantrine pharmaco-
kinetic model can be found in S2 Text.
Discussion
The population pharmacokinetic model based on this covariate-rich dataset from nearly 4,000
patients provides an improved understanding of how body weight, pregnancy, dosage, and
admission parasitaemia affect the absorption, distribution, and elimination of the most impor-
tant and widely used anti-malarial therapy in current use. By applying a pharmacokinetic-
pharmacodynamic time-to-event model to this dataset, we have made, to the best of our
knowledge, the first comprehensive attempt to evaluate the relationship between pharmacoki-
netic factors and AL treatment outcome (PCR-corrected recrudescent malaria infections)
across different geographical areas and populations. The lumefantrine/desbutyl-lumefantrine
population pharmacokinetic model provides an improved understanding of the disposition
effect of lumefantrine’s main active metabolite, which had hitherto remained poorly character-
ised. Young children and pregnant women have lower lumefantrine exposures compared with
non-pregnant adults. The reason that young children have relatively low lumefantrine expo-
sure is that currently recommended AL dosage regimens do not adjust adequately for the non-
linear relationship between body weight and systemic exposure. Pregnant women were under-
exposed due to changes in the distribution kinetics of lumefantrine. Underexposure in these
vulnerable populations contributes to lower cure rates and the selection of parasite resistance.
In silico dose optimisations utilising the lumefantrine population pharmacokinetic model pro-
vide a sound basis for proposing improved dosing regimens for these 2 vulnerable groups.
Lumefantrine pharmacokinetic model
Lumefantrine exposure and day 7 concentrations decreased substantially with increasing base-
line parasite densities [16]. Higher parasitaemias reflect more severe disease, which could
reduce the absorption as a result of reductions in visceral blood flow. The dose dependency of
lumefantrine absorption was consistent with a previous study from the Thailand–Myanmar
border in which lumefantrine exposure in patients with uncomplicated malaria was 30% lower
when once-daily doses were administered compared to when the same dose was divided
between 2 daily doses [14].
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Weight-for-age z-score did not significantly improve the model fit when embedded in
absorption, clearance, or distribution parameters. However, a pooled analysis on lumefantrine
treatment outcome and day 7 concentration data showed a substantially higher risk of recru-
descent malaria and lower concentrations at day 7 with decreasing weight-for-age z-scores
[16,46]. Most probably the discrepancy between these 2 findings could be explained by the dis-
tribution of weight-for-age z-scores, which in this study had a large proportion of well-nour-
ished (z-score between −2 and +2) children (214/281 children <5 years and 108/139 children
<3 years). Moreover, weight-for-age z-score is an anthropometric indicator of both long-term
(stunting) and short-term (wasting) nutritional status. The majority of the population studied
here did not suffer from malnutrition, which could have affected significantly absorption, in
Table 4. Population parameter estimates from the simultaneous pharmacokinetic lumefantrine/desbutyl-lume-
fantrine drug-metabolite model.
Parameter Fixed effects Random effects
Population estimate
(BS estimate)
%RSE (95% CI
parameter estimate)
%CV for IIV (BS
estimate)
%RSE (95% CI
parameter estimate)
F 1 (fixed) — 57.9 (57.2) 57.2 (49.0 to 64.9)
Box–Cox shape
parameter on F
−0.449 (−0.459) 35.5 (−0.793 to
−0.126)
— —
ka (h−1) 0.0409 (0.0422) 13.3 (0.0349 to 0.0567) — —
CLLF/F (l/h) 1.56 (1.57) 6.24 (1.40 to 1.77) — —
VC LF/F (l) 21.2 (21.6) 19.5 (14.6 to 30.5) 111 (110) 110 (87.5 to 134)
QLF/F (l/h) 0.381 (0.387) 11.3 (0.313 to 0.497) — —
VP LF/F (l) 53.8 (54.5) 8.60 (46.2 to 65.2) — —
CLDLF/F (l/h) 78.4 (77.4) 7.80 (64.6 to 88.5) 38.8 (39.8) 39.8 (32.0 to 51.0)
VC DLF/F (l) 2,470 (2,560) 13.1 (1,960 to 3,280) 86.0 (82.3) 82.3 (49.5 to 110)
QDLF/F (l/h) 104 (103) 13.2 (78.3 to 131) 34.9 (33.8) 33.8 (0.339 to 53.0)
VP DLF/F (l) 8,650 (8,870) 14.2 (6,990 to 11,800) 47.7 (45.3) 45.3 (0.453 to 68.9)
Dose50 (mg/kg) on F 3.86 (fixed) — — —
Pregnancy on ka 0.513 (0.543) 52.4 (0.264 to 0.889) — —
Parasitaemia on F −0.226 (−0.218) 81.8 (−0.557 to 0.156) — —
σLF 0.251 (0.251) 11.8 (0.196 to 0.315) — —
σDLF 0.0560 (0.0559) 8.46 (0.0467 to 0.0657) — —
Coefficient of variation (%CV) for inter-individual variability (IIV) was calculated as 100
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
eestimate   1
p
. The relative
standard error (%RSE) was calculated as 100 Standard deviationAverage parameter estimate from 1,000 iterations of a non-parametric bootstrap
(BS) procedure. The 95% confidence interval (95% CI) is displayed as the 2.5th to 97.5th percentile of the BS
estimate, and the BS estimate as the average value.
LF: lumefantrine; DLF: desbutyl-lumefantrine; F: relative bioavailability; Box–Cox shape parameter: shape parameter
on Box–Cox transformation; ka: absorption rate constant; VC/F: apparent central volume of distribution; VP/F:
apparent peripheral volume of distribution; Q/F: inter-compartmental clearance; CL/F: elimination clearance; and σ:
residual error additive on log scale. All parameters were centred around a non-pregnant patient with an admission
parasitaemia of 15,800 parasites/μl, and clearance and volume parameters were centred around a non-pregnant
patient weighing 42 kg and scaled allometrically (CL=Q ¼ y nð Þ  WT
42
3
4; V ¼ y nð Þ  WT
42
); parasitaemia was coded as
in its logarithm in an exponential relationship centred around the mean (F ¼ yðnÞ  eyparasitaemia  ðparasitaemia  4:2Þ), and a
categorical pregnancy effect on ka was coded as follows: ka = θ × (1 + θpregnant).
Pregnancy was a categorical/proportional covariate on F [1 + θ], dose50 was implemented using a saturation model
on F [1 − (Dose/(θ + Dose))], and admission parasitaemia was implemented using a power relationship on F
[(parasitaemia/median value)θ].
https://doi.org/10.1371/journal.pmed.1002579.t004
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contrast to the larger sample size studied previously. Weight-for-height z-scores may be a
superior proxy for acute global malnutrition, especially in relation to drug pharmacology, but
height was not available for all patients in the database.
Including age as a maturation factor for lumefantrine elimination clearance did not signifi-
cantly improve the model fit. Maturation of enzymatic activity occurs during the first 2 years
[12], and the lack of data in the youngest children (in the model building dataset the youngest
child was 6 months old and only 4 patients were below 1 year) might explain the absence of
this covariate relationship.
An earlier meta-analysis of observed lumefantrine concentrations at day 7 that included
2,787 patients indicated substantially lower lumefantrine concentrations on day 7 in patients
with documented fever (i.e., >37.5˚C admission axillary temperature) compared to patients
without fever [16]. Also, filter paper dried capillary blood lumefantrine concentrations at day 7
were lower with increasing haemoglobin levels in the same analysis [16]. Admission body tem-
perature and haemoglobin were evaluated here in a separate covariate analysis on a subset of
data, but were not included in the final lumefantrine population pharmacokinetic model since
these covariates were missing for more than 20% of the patients. In the patients in whom it
was recorded, admission body temperature did not correlate significantly with any lumefan-
trine pharmacokinetic parameter in the current population pharmacokinetic model. The hae-
moglobin concentration did correlate with lumefantrine inter-compartmental clearance and
apparent peripheral distribution volume, and, in contrast to previously published work, the
results suggested somewhat higher lumefantrine concentrations at day 7 with increasing hae-
moglobin levels. However, the sampling matrix in this study was venous plasma as opposed to
whole blood in filter paper, as in the previously reported study. Results should therefore be
interpreted with caution.
Potential differences in lumefantrine distribution in venous blood and capillary blood
when compared to venous plasma might not have been captured as venous and capillary blood
samples were taken only at 7 days after treatment initiation. Thus, the reported proportional
differences should be interpreted with caution. Increased lumefantrine exposures with crushed
and dispersible tablets were in line with published results in healthy volunteers [47]. However,
similarly to the interpretation of matrix effects, proportional differences for formulation effects
should be interpreted cautiously as the sparse sampling design (i.e., 1 sample per patient) pre-
vented formal evaluation of bioequivalence. Matrix and formulation effects need further evalu-
ation in prospective clinical studies before firm conclusions can be drawn.
Lumefantrine pharmacokinetic-pharmacodynamic time-to-event model
No statistically significant clinical covariates could be found in the pharmacokinetic-pharma-
codynamic time-to-event model. This indicated that treatment failures in vulnerable patient
groups (e.g., children below 5 years of age and pregnant women) could be explained fully by
reduced lumefantrine exposures.
However, the artemether/dihydroartemisinin drug effect was not included in the lumefan-
trine pharmacokinetic-pharmacodynamic time-to-event model nor was a desbutyl-lumefan-
trine effect [48]. Consequently, all pharmacodynamic parameters, including baseline hazard
and hazard half-life, are apparent, as the lumefantrine drug effect in the current pharmacoki-
netic-pharmacodynamic time-to-event model actually represents the sum of the artemether/
dihydroartemisinin and lumefantrine/desbutyl-lumefantrine drug effects. Thus, the developed
time-to-event model was not used for in silico dose optimisations because of the above issue in
combination with poor parameter precision and accuracy of the pharmacokinetic-pharmaco-
dynamic lumefantrine model.
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In silico dose optimisation
The high cure rates and excellent tolerability observed in non-pregnant adult patient popula-
tions suggest that conventional dosing in this group results in drug exposures within acceptably
safe and effective therapeutic margins in most patients. Therefore, it is reasonable that dosage
recommendations for other groups (including children and pregnant women) should be based
on therapeutic targets that aim to achieve similar lumefantrine exposure (AUC and day 7 con-
centrations) to that of non-pregnant adults. This could improve cure rates in these groups and
reduce the risks of drug resistance that could shorten AL’s useful therapeutic life [2].
Administering higher individual doses at the currently recommended frequency and dura-
tion (i.e., by adding extra tablets to each dose in the usual twice-daily regimen) failed to result in
proportional linear increases in overall drug exposures across all target populations. This pre-
sumably reflects dose-limited absorption. We modelled an additional 2 alternative dosing regi-
mens: an intensified regimen (thrice-daily dosing with the currently recommended weight-
based number of tablets per dose) and an extended regimen (with the currently recommended
weight-based number of tablets per dose given twice daily for 5 days). Enrolment parasite density
was not taken into account in dose optimisation simulations since quantification of parasites at
enrolment is not always possible. Both alternative dosing regimens resulted in similar or higher
lumefantrine concentrations on day 7 and AUCs than in non-pregnant adults given the cur-
rently recommended standard dosing regimen. However, higher maximum concentrations were
not seen in these simulations, suggesting that pregnant women and young children receiving
these regimens would not face added risks of peak drug exposure-related acute toxicity, although
further investigation in prospective clinical studies would be required to confirm this [6].
From a pharmacological perspective, a dose extension (i.e., twice-daily dosing at the current
dosage for 5 days) for children25 kg and pregnant women during the second and third tri-
mester probably has the greatest advantages for therapeutic efficacy. A dose extension would
result not only in adequate lumefantrine exposures but also, even more importantly, in an
additional malaria asexual replication cycle being exposed to artemether/dihydroartemisinin.
This would contribute to a lower parasite biomass. Unfortunately, artemether/dihydroartemi-
sinin concentration-time data were not available in this study, which prevented us from formal
clinical trial simulations using a pharmacokinetic-pharmacodynamic time-to-event approach
for PCR-confirmed recrudescent malaria at day 42.
An extended dosing regimen needs to be considered in light of greater challenges in ensur-
ing adherence to longer courses of anti-malarials. A 4-day treatment might be an option if a
5-day treatment is not possible due to poor adherence and/or cost issues. The alternative
approach of intensifying frequency may also have programmatic disadvantages including dos-
ing compliance with a more complex regimen and the need for repackaging, which increases
the burden on pharmaceutical companies. The current development of a new formulation that
provides increased lumefantrine absorption in animal and healthy volunteer studies might
provide a solution [49,50]. Nevertheless, until this formulation is commercially available, the
efficacy, safety, and tolerability of the proposed regimens with the conventional formulation in
children and pregnant women will require further evaluation in prospective clinical trials.
Moreover, the population pharmacokinetic model developed in this study can be used for dose
optimisation of the novel formulation as lumefantrine metabolism and elimination will remain
the same.
Study limitations
The developed lumefantrine population pharmacokinetic model and subsequent evaluation of
alternative dosing regimens have a number of limitations. Model development was conducted
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using venous plasma data from patients receiving intact tablets administered with fat. Simula-
tions, including evaluations and comparisons of alternative dosing regimens, are consequently
representative only for venous plasma after administration of intact tablets with fat. Adjust-
ments for sampling matrix (i.e., venous blood, capillary blood, or capillary plasma) or formula-
tion (i.e., crushed or dispersible tablets) were not performed since correction factors were not
considered reliable due to the sparseness of data. Furthermore, all patients included in this
analysis received AL with fat, eliminating the possibility to characterise and quantify the
impact of concomitant fat intake on the bioavailability of lumefantrine. The absence of arte-
mether-dihydroartemisinin data prevented a full evaluation of AL therapy. Consequently,
lumefantrine concentrations at day 7 were used as a pharmacokinetic endpoint. Nevertheless,
the model remains clinically relevant considering that the vast majority of patients are treated
with intact tablets co-administered with fat.
After the database was closed, 7 studies meeting the inclusion criteria were published (S2
Table) [10,12,13,51–54]. Two studies in Malawi and Uganda evaluated lumefantrine pharma-
cokinetic drug–drug interactions with anti-retroviral therapies for HIV-co-infected paediatric
patients [52,54]. Drug–drug interaction data were not available in the pooled lumefantrine
pharmacokinetic database, and therefore, these data would not have made a substantial impact
on the analysis presented here. A total of 3 studies in pregnant women with uncomplicated
P. falciparum malaria in Tanzania and Uganda were identified [10,13,53]. All women studied
were in their second and third trimester. Pregnant women in Tanzania and Uganda displayed
a similar pattern of decreased lumefantrine exposure compared to non-pregnant women as in
this pooled analysis [10,53]. Unlike this pooled analysis, a study in Uganda did not report sig-
nificant differences in lumefantrine exposure in pregnant and non-pregnant women, but a less
powerful non-parametric, non-compartmental analysis was used, which could potentially
explain this discrepancy [13]. A study in Mali and Niger in severely malnourished children
(weight-for-height z-score< –3) between 6 months and 5 years found lower lumefantrine con-
centrations at day 7 compared to matched nourished children (weight-for-height z-score
–3) [51]. This pattern of lumefantrine underexposure with malnourishment was not apparent
in this pooled study, a finding most likely explained by a discrepancy in z-score distributions,
with a larger proportion of well-nourished (z-score between −2 and +2) children (214/281 chil-
dren <5 years and 108/139 children <3 years) in the pooled analysis presented here. The
impact of malnutrition on lumefantrine exposure needs to be evaluated further in a large
pooled analysis including severely, moderately, and non-malnourished children from different
regions. In line with the results presented here, a paediatric study in Uganda reported body
weight as an allometric covariate for clearance and volume parameters, resulting in relatively
lower lumefantrine exposure in small children [12]. However, a positive correlation between
lumefantrine exposure and age was also identified in the children in Uganda. In the pooled
analysis presented here, baseline parasitaemia displayed a negative correlation with exposure.
Thus, these correlated covariates (age and baseline parasitaemia correlate negatively) might be
a likely explanation for the apparent discrepancy between the 2 studies.
Conclusions
Conventional weight-based dosing in young children (25 kg) and pregnant women resulted
in significantly lower lumefantrine drug exposures when compared to non-pregnant adults,
and this may underpin poorer cure rates in these particularly vulnerable groups. Substantial
dose-limited absorption of lumefantrine using the currently available formulation limits
opportunities to improve drug exposure in these groups by just escalating the amount of drug
administered with each dose. However, pharmacokinetic model-based simulations of
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alternative strategies suggest that, assuming similar adherence, intensified (3 times daily for 3
days) or extended (2 times daily for 5 days) dose regimens could result in equivalent lumefan-
trine exposures to those of non-pregnant adults treated conventionally. An extended dosing
regimen is most favourable from a pharmacological perspective as an additional malaria
asexual replication cycle is thereby exposed to artemether/dihydroartemisinin, which will
undoubtedly contribute to increased parasitological killing. Given that AL is now the most
widely used drug for treating the global burden of malaria illness, estimated at>200 million
cases annually, prospective clinical dose optimisation studies evaluating efficacy, safety, and
tolerability, as well as both artemether/dihydroartemisinin and lumefantrine/desbutyl-lume-
fantrine pharmacokinetics, are now warranted in order to provide in vivo confirmation of our
in silico findings for these proposed dosing regimens. Future research should also include eval-
uations of the regimens’ acceptability and adherence in order to determine the feasibility, prac-
ticality, and effectiveness of longer or more intense regimens. Implementing improved dosing
regimens may have implications for reducing treatment failures in these vulnerable popula-
tions. Young African children represent the largest and most important population affected by
malaria, and pregnant women are at higher risk of severe complications, death, and adverse
pregnancy outcomes due to malaria. Improved dosing also has the potential benefit of limiting
sub-therapeutic drug exposures at a population level, thereby reducing the risk of drug resis-
tance and extending the therapeutic life of this important artemisinin-based combination
treatment.
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